ATE509954T1 - Anti-cd19-antikörper mit reduzierter immunogenität - Google Patents
Anti-cd19-antikörper mit reduzierter immunogenitätInfo
- Publication number
- ATE509954T1 ATE509954T1 AT06829801T AT06829801T ATE509954T1 AT E509954 T1 ATE509954 T1 AT E509954T1 AT 06829801 T AT06829801 T AT 06829801T AT 06829801 T AT06829801 T AT 06829801T AT E509954 T1 ATE509954 T1 AT E509954T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- variable region
- regions
- modified
- chain variable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75560905P | 2005-12-30 | 2005-12-30 | |
PCT/EP2006/012365 WO2007076950A1 (en) | 2005-12-30 | 2006-12-21 | Anti-cd19 antibodies with reduced immunogenicity |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE509954T1 true ATE509954T1 (de) | 2011-06-15 |
Family
ID=37865674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06829801T ATE509954T1 (de) | 2005-12-30 | 2006-12-21 | Anti-cd19-antikörper mit reduzierter immunogenität |
Country Status (15)
Country | Link |
---|---|
US (4) | US8691952B2 (de) |
EP (2) | EP2270050B1 (de) |
JP (2) | JP2009521912A (de) |
KR (1) | KR101397290B1 (de) |
CN (1) | CN101351477B (de) |
AT (1) | ATE509954T1 (de) |
AU (1) | AU2006332155B2 (de) |
BR (1) | BRPI0620795A2 (de) |
CA (1) | CA2635623C (de) |
DK (2) | DK1966245T3 (de) |
EA (1) | EA016429B1 (de) |
ES (2) | ES2365046T3 (de) |
PT (2) | PT2270050E (de) |
WO (1) | WO2007076950A1 (de) |
ZA (1) | ZA200806609B (de) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
CA2446087C (en) | 2001-05-03 | 2013-06-18 | Stephen D. Gillies | Recombinant tumor specific antibody and use thereof |
EP1454138B1 (de) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokine mit modulierter selektivität |
BRPI0418286A (pt) * | 2003-12-30 | 2007-05-02 | Merck Patent Gmbh | proteìnas de fusão de il-7 |
KR20060124656A (ko) * | 2003-12-31 | 2006-12-05 | 메르크 파텐트 게엠베하 | 개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질 |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
US8444973B2 (en) * | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
CA2635623C (en) * | 2005-12-30 | 2015-02-17 | Michael Super | Anti-cd19 antibodies with reduced immunogenicity |
US20070166306A1 (en) * | 2006-01-17 | 2007-07-19 | Fey Georg H M | Anti-CD19 antibody composition and method |
WO2008022152A2 (en) | 2006-08-14 | 2008-02-21 | Xencor, Inc. | Optimized antibodies that target cd19 |
ATE551071T1 (de) | 2006-09-08 | 2012-04-15 | Medimmune Llc | Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen |
PL2167128T3 (pl) * | 2007-07-17 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii hybrydowe przeciwciała skierowane przeciwko integrynie alfa-v |
JP5727786B2 (ja) | 2007-10-19 | 2015-06-03 | シアトル ジェネティクス,インコーポレーテッド | Cd19結合性物質およびその使用 |
WO2009097140A1 (en) * | 2008-01-30 | 2009-08-06 | Memorial Sloan-Kettering Cancer Center | Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors |
US10350243B2 (en) | 2008-01-30 | 2019-07-16 | Memorial Sloan-Kettering Cancer Center | Methods for off-the-shelf-tumor immunotherapy using allogeneic T-cell precursors |
BRPI0910484A2 (pt) * | 2008-04-25 | 2018-03-27 | Merck Patent Gmbh | esqueletos artificiais de proteína |
SG175233A1 (en) * | 2009-04-22 | 2011-11-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
EP2409712A1 (de) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19-Antikörper mit ADCC- und CDC-Funktionen und verbessertem Glykosylierungsprofil |
EP2409993A1 (de) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19-Antikörper mit ADCC-Funktionen und verbessertem Glykosylierungsprofil |
SI2672994T1 (sl) | 2011-02-11 | 2018-09-28 | Merck Patent Gmbh | Protitelo proti alfa-v integrinu za zdravljenje raka prostate |
ES2909722T3 (es) | 2011-08-16 | 2022-05-10 | Morphosys Ag | Terapia de combinación con un anticuerpo anti-CD19 y una mostaza nitrogenada |
SI2744826T1 (sl) | 2011-08-16 | 2022-05-31 | Morphosys Ag | Kombinirana terapija s protitelesom proti CD19 in analogom purina |
CN105102068B (zh) | 2012-10-12 | 2018-06-01 | Adc疗法责任有限公司 | 吡咯并苯并二氮杂卓-抗体结合物 |
DK2906298T3 (en) * | 2012-10-12 | 2018-12-17 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
CN107660151B (zh) | 2015-05-26 | 2022-03-11 | 莫佛塞斯公司 | 抗-cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途 |
MX2018002241A (es) | 2015-08-21 | 2018-03-23 | Morphosys Ag | Combinaciones y sus usos. |
CN109313194B (zh) | 2016-05-30 | 2022-11-04 | 莫佛塞斯公司 | 预测cd19抗体治疗在患者中的治疗益处的方法 |
PT3475303T (pt) | 2016-06-27 | 2021-06-25 | Morphosys Ag | Formulações de anticorpos anti-cd19 |
RS62036B1 (sr) | 2016-10-28 | 2021-07-30 | Morphosys Ag | Kombinacija anti cd19 antitela sa bcl-2 inhibitorom i njihova upotreba |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
CN108690138A (zh) * | 2017-04-12 | 2018-10-23 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用 |
SG11201909715VA (en) | 2017-05-31 | 2019-11-28 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
TWI832818B (zh) * | 2017-07-07 | 2024-02-21 | 南韓商韓美藥品股份有限公司 | 新穎的治療性酵素融合蛋白及其用途 |
JP7279011B2 (ja) | 2017-07-10 | 2023-05-22 | インターナショナル-ドラッグ-ディベロップメント-バイオテック | 抗cd20抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗cd19抗体を用いるb細胞悪性の治療 |
NZ765453A (en) * | 2017-12-22 | 2024-03-22 | Hanmi Pharmaceutical Co Ltd | Therapeutic enzyme fusion protein having novel structure and use thereof |
CN114072424A (zh) | 2019-05-03 | 2022-02-18 | 莫佛塞斯公司 | 具有有限数量的nk细胞的患者中的抗cd19疗法 |
JP2022550435A (ja) | 2019-10-04 | 2022-12-01 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | 組換えaavの改善された治療的使用のための方法 |
MX2022005033A (es) | 2019-10-31 | 2022-09-09 | Morphosys Ag | Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta. |
MX2022005031A (es) | 2019-10-31 | 2022-07-27 | Morphosys Ag | Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas. |
CN111018988B (zh) * | 2019-11-26 | 2021-09-21 | 山东立菲生物产业有限公司 | 一种抗cd19的抗体、制备方法及其应用 |
AR121370A1 (es) | 2020-02-28 | 2022-06-01 | Lilly Co Eli | Anticuerpos anti-cd19 humano |
EP4168449A1 (de) | 2020-06-22 | 2023-04-26 | MorphoSys AG | Anti-tumor-kombinationstherapie mit anti-cd19-antikörper und polypeptiden zur blockierung des angeborenen immuncheckpoints sirpa-cd47 |
EP4225794A1 (de) | 2020-10-06 | 2023-08-16 | Xencor, Inc. | Biomarker, verfahren und zusammensetzungen zur behandlung von autoimmunerkrankungen mit systemischem lupus erythematous (sle) |
WO2022117799A2 (en) | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
WO2024038115A1 (en) | 2022-08-17 | 2024-02-22 | Morphosys Ag | Therapy comprising anti-cd19 antibody and ezh2 modulators |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5082658A (en) * | 1984-01-16 | 1992-01-21 | Genentech, Inc. | Gamma interferon-interleukin-2 synergism |
US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5679543A (en) * | 1985-08-29 | 1997-10-21 | Genencor International, Inc. | DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5359035A (en) * | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
ATE122238T1 (de) | 1987-06-10 | 1995-05-15 | Dana Farber Cancer Inst Inc | Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen. |
US5064646A (en) | 1988-08-02 | 1991-11-12 | The University Of Maryland | Novel infectious bursal disease virus |
DE3880766D1 (de) | 1987-09-02 | 1993-06-09 | Ciba Geigy Ag | Konjugate von interferon alpha mit immunglobulinen. |
US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
ATE108068T1 (de) | 1987-09-23 | 1994-07-15 | Bristol Myers Squibb Co | Antikörper-heterokonjugate zur töting von hiv- infizierten zellen. |
PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
CA1341588C (en) | 1988-01-26 | 2009-01-06 | Michel Revel | Human ifn-beta2/i1-6, its purification and use |
DE3812605A1 (de) | 1988-04-15 | 1990-06-07 | Leskovar Peter Dipl Ing Dr Hab | Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes |
US4975369A (en) * | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
IT1217724B (it) | 1988-05-26 | 1990-03-30 | Ist Naz Ric Sul Cancro | Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori |
US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US6291158B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
ES2187598T3 (es) | 1989-09-20 | 2003-06-16 | Abbott Lab | Metodos para producir proteinas de fusion. |
US5196320A (en) * | 1989-09-20 | 1993-03-23 | Abbott Biotech, Inc. | Method of producing engineered binding proteins |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
JPH07507440A (ja) | 1990-03-02 | 1995-08-24 | レプリゲン・コーポレーション | 結合親和性を高めた抗体構築物 |
HUT60768A (en) * | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
EP0541716A1 (de) | 1990-07-27 | 1993-05-19 | Repligen Corporation | Neuartige methoden und zusammensetzungen zur behandlung von gefässerkrankungen |
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
JPH09506761A (ja) | 1990-11-09 | 1997-07-08 | ステファン ディー.ギリーズ | サイトカインの免疫複合体 |
EP0556328A4 (en) | 1990-11-09 | 1994-06-08 | Abbott Lab | Bridging antibody fusion constructs |
WO1992010755A1 (en) | 1990-12-05 | 1992-06-25 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
US6072039A (en) | 1991-04-19 | 2000-06-06 | Rohm And Haas Company | Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest |
US6797492B2 (en) * | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
WO1993003157A1 (en) | 1991-07-29 | 1993-02-18 | Dana Farber Cancer Institute | Plasmids for the rapid preparation of modified proteins |
WO1993005169A1 (en) | 1991-08-30 | 1993-03-18 | Fred Hutchinson Cancer Research Center | Hybrid cytokines |
US20020037558A1 (en) * | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
US6627615B1 (en) * | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
GB9206422D0 (en) * | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
AU4528493A (en) * | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
DE69332485T2 (de) * | 1992-08-11 | 2003-11-13 | Harvard College | Immunmodulierende peptide |
DE4228839A1 (de) | 1992-08-29 | 1994-03-03 | Behringwerke Ag | Verfahren zum Nachweis und zur Bestimmung von Mediatoren |
US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5837821A (en) * | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
AU6776194A (en) | 1993-04-28 | 1994-11-21 | Hybritech Incorporated | Method for creating optimized regulatory regions affecting protein expression and protein trafficking |
US5554512A (en) * | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
US5888773A (en) * | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
AU5985996A (en) | 1995-06-07 | 1997-01-15 | Osteosa Inc. | Osteoclast growth regulatory factor |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
WO1997030089A1 (en) | 1996-02-13 | 1997-08-21 | Regents Of The University Of California | Novel antibody-cytokine fusion protein, and methods of making and using the same |
US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
EP0983303B1 (de) | 1997-05-21 | 2006-03-08 | Biovation Limited | Verfahren zur herstellung von nicht-immunogenen proteinen |
GB9712892D0 (en) | 1997-06-20 | 1997-08-20 | Eclagen Ltd | Identification of mhc binding peptides |
DE69838552T2 (de) | 1997-07-14 | 2008-05-21 | Bolder Biotechnology, Inc., Louisville | Derivate des wachstumshormons und verwandte proteine |
DK1037927T3 (da) * | 1997-12-08 | 2004-09-06 | Emd Lexigen Res Ct Corp | Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
BR9909583A (pt) * | 1998-04-15 | 2002-01-15 | Lexigen Pharm Corp | Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese |
HUP0101343A3 (en) * | 1998-04-17 | 2003-10-28 | Lexigen Pharmaceuticals Corp L | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
WO1999058662A1 (fr) | 1998-05-14 | 1999-11-18 | Merck Patent Gmbh | Proteine fusionnee |
GB9814383D0 (en) | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
EP1107989B1 (de) * | 1998-08-25 | 2010-03-31 | Merck Patent GmbH | Expression und export von angiostatin und endostatin als immunofusins |
US6646113B1 (en) * | 1998-09-17 | 2003-11-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants |
US6335176B1 (en) * | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
KR20020007287A (ko) * | 1999-01-07 | 2002-01-26 | 추후보정 | Fc 융합 단백질로서 항-비만 단백질의 발현 및 이출 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
DE60035871T2 (de) * | 1999-05-19 | 2008-06-05 | Merck Patent Gmbh | Expression und export von interferon-alpha proteinen als fc fusionsproteine |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US7067110B1 (en) * | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
CA2380331C (en) | 1999-08-09 | 2012-11-20 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
JP5179689B2 (ja) * | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
CN1270775C (zh) * | 2000-06-29 | 2006-08-23 | 默克专利有限公司 | 通过与免疫细胞因子摄入促进剂联合治疗来增强抗体-细胞因子融合蛋白介导的免疫反应 |
US6475707B2 (en) * | 2000-12-22 | 2002-11-05 | United Microelectronics Corp. | Method of reworking photoresist layer |
CN1268394C (zh) | 2001-01-17 | 2006-08-09 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002057435A2 (en) * | 2001-01-18 | 2002-07-25 | Merck Patent Gmbh | Bifunctional fusion proteins with glucocerebrosidase activity |
EP1998266A3 (de) | 2001-02-19 | 2009-02-11 | Merck Patent GmbH | Verfahren zur Identifizierung von T-Zell-Epitopen und Verfahren zur Herstellung von Molekülen mit verminderter Immunogenität |
AU2002233340B2 (en) * | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
CA2446087C (en) * | 2001-05-03 | 2013-06-18 | Stephen D. Gillies | Recombinant tumor specific antibody and use thereof |
EP1454138B1 (de) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokine mit modulierter selektivität |
US6736056B1 (en) * | 2002-11-15 | 2004-05-18 | A Marek Ken Company | Manual ink applicator |
ATE471946T1 (de) * | 2002-12-17 | 2010-07-15 | Merck Patent Gmbh | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 |
US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
BRPI0418286A (pt) * | 2003-12-30 | 2007-05-02 | Merck Patent Gmbh | proteìnas de fusão de il-7 |
KR20060124656A (ko) * | 2003-12-31 | 2006-12-05 | 메르크 파텐트 게엠베하 | 개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질 |
ES2330860T3 (es) * | 2004-01-22 | 2009-12-16 | Merck Patent Gmbh | Anticuerpos anticancerosos con fijacion del complemento reducida. |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
DE602005020837D1 (de) * | 2004-12-09 | 2010-06-02 | Merck Patent Gmbh | Il-7-varianten mit reduzierter immunogenität |
EP1904101A4 (de) * | 2005-06-08 | 2011-06-15 | Univ Duke | Anti-cd19-antikörper-therapie für transplantation |
CA2635623C (en) | 2005-12-30 | 2015-02-17 | Michael Super | Anti-cd19 antibodies with reduced immunogenicity |
-
2006
- 2006-12-21 CA CA2635623A patent/CA2635623C/en active Active
- 2006-12-21 ES ES06829801T patent/ES2365046T3/es active Active
- 2006-12-21 KR KR1020087018761A patent/KR101397290B1/ko active IP Right Grant
- 2006-12-21 JP JP2008547885A patent/JP2009521912A/ja not_active Withdrawn
- 2006-12-21 BR BRPI0620795-2A patent/BRPI0620795A2/pt not_active Application Discontinuation
- 2006-12-21 AT AT06829801T patent/ATE509954T1/de active
- 2006-12-21 EA EA200870132A patent/EA016429B1/ru not_active IP Right Cessation
- 2006-12-21 ES ES10008056T patent/ES2426468T3/es active Active
- 2006-12-21 DK DK06829801.7T patent/DK1966245T3/da active
- 2006-12-21 EP EP10008056.3A patent/EP2270050B1/de active Active
- 2006-12-21 EP EP06829801A patent/EP1966245B1/de active Active
- 2006-12-21 CN CN2006800498114A patent/CN101351477B/zh active Active
- 2006-12-21 WO PCT/EP2006/012365 patent/WO2007076950A1/en active Application Filing
- 2006-12-21 DK DK10008056.3T patent/DK2270050T3/da active
- 2006-12-21 AU AU2006332155A patent/AU2006332155B2/en active Active
- 2006-12-21 PT PT100080563T patent/PT2270050E/pt unknown
- 2006-12-21 PT PT06829801T patent/PT1966245E/pt unknown
- 2006-12-29 US US11/648,505 patent/US8691952B2/en active Active
-
2008
- 2008-07-29 ZA ZA200806609A patent/ZA200806609B/xx unknown
-
2014
- 2014-03-21 US US14/222,517 patent/US8957195B2/en active Active
-
2015
- 2015-02-12 US US14/620,955 patent/US10072092B2/en active Active
- 2015-08-25 JP JP2015165965A patent/JP6104332B2/ja active Active
-
2018
- 2018-09-10 US US16/126,296 patent/US11208496B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE509954T1 (de) | Anti-cd19-antikörper mit reduzierter immunogenität | |
DE602005007429D1 (de) | Schaufel mit Sammelkammer an ihrer Spitze | |
WO2007041470A3 (en) | High-protein soy-wheat crisps | |
DE602005012039D1 (de) | Thermoplastische Vulkanisate mit verbesserter Herstellbarkeit. | |
WO2006104989A3 (en) | Altered antibody fc regions and uses thereof | |
EP1816140A4 (de) | Anti-glypican-3-antikörper mit modifizierter zuckerkette | |
ATE349489T1 (de) | Multimodale polyethylenzusammensetzung mit verbesserter homogenität | |
WO2003068801A3 (en) | Antibody variants with faster antigen association rates | |
WO2007056470A3 (en) | Neuropilin antagonists | |
WO2009024509A3 (de) | Solarzellenaufbau | |
ATE518859T1 (de) | Neue fluorenderivate, zusammensetzung mit diesen derivaten und verwendung | |
WO2007008943A3 (en) | Optimized anti-ep-cam antibodies | |
ATE485941T1 (de) | Werkstoffverbund mit explosionsgeschweisstem zwischenstück | |
ATE497074T1 (de) | Sich selbst aufschlagendes zelt | |
WO2007030014A8 (en) | Homologous recombination in plants | |
ATE434094T1 (de) | Dachfensterrahmen und dessen herstellungsverfahren | |
DE602006016004D1 (de) | VERBESSERTE MULTI-KUPFER-OXIDASE CueO MIT FÄRBEVERMÖGEN | |
FR2865729B1 (fr) | Composiion de verre silico-sodo-calcique | |
WO2007044115A3 (en) | Improved chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax | |
DE102004014505A1 (de) | Schmuckkette mit beweglich gehaltenen Kettengliedern | |
DE112006002466A5 (de) | Kettenlasche, disee beinhaltende Kette, sowie damit gebildeter Kettentrieb und damit ausgerüstetes Fahrzeug | |
EP1959009A4 (de) | Genetisch rekombinanter anti-perp-antikörper | |
FR2876095B1 (fr) | Composition de verre silico-sodo-calcique | |
FR2845898B1 (fr) | Composition cosmetique associant au moins deux matieres colorantes dont au moins une matiere colorante photochrome. | |
ITTO20040853A1 (it) | Procedimento per la preparazione di articoli di vetro cellulare rivestiti e articoli cosi' ottenuti. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1966245 Country of ref document: EP |